Henry Ford Hospital expands research on gene and radiation therapy for prost...(which treatment is most effective. ...),Health
Navigation Links
Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
Date:2/6/2008
which treatment is most effective.
'/>"/>
| Contact: Zoila Brown zbrown1@hfhs.org 313-874-7207 Henry Ford Health System Source:Eurekalert |
Related medicine news :
1. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
2. AAPD to Present 2008 Henry B. Betts Award to International Human Rights Disability Advocate Eric Rosenthal
3. Michigan Quality Council (MQC) Names Henry Ford Health System 2007 State Quality Award Recipient
4. Repligen Elects Earl Henry, M.D. to the Board of Directors
5. Program for Stroke Survivors and Friends Hosted by Henry Ford Hospital
6. Fund-Raiser for Henry Ford Hospitals Stroke Program
7. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
8. Grosse Pointes Cottage Hospital Joins Henry Ford Health System
9. New Rhode Island Hospital study shows inadequate diagnostic criteria for eating disorders
10. IPC The Hospitalist Company, Inc. Announces Closing of IPO and Exercise of Underwriters Over-Allotment Option
11. Jacobs Receives Contract from Catholic Healthcare West to Assist Sequoia Hospital Expansion Program
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2Health News:Study shows how gene action may lead to diabetes prevention, cure 2Health News:Better Vaccine Planning Needed, Committee Finds 2Health News:Better Vaccine Planning Needed, Committee Finds 3Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 2Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 3Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 4Health News:Controversy Over Reid Fundraiser Exemplifies Need for Fair Elections 2
[0] Clinical trial advances new approach to re-sensitizing breast cancer[0] Study shows how gene action may lead to diabetes prevention, cure[0] Better Vaccine Planning Needed, Committee Finds[0] Effort to Regenerate Injured Spinal Cords Turns to a New Model[0] Controversy Over Reid Fundraiser Exemplifies Need for Fair Elections
Other Medicine News:Health News:2008 Presidential Hopefuls Fail to Respond to Questions About Obesity in U.S. 2Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:Oakwood is First Healthcare System in Southeast Michigan to Post Pricing Information on Web Site 2Health News:Hooters of Gulfport Makes the Largest Contribution towards the $250,000 Donation to the V Foundation for Cancer Research 2Health News:Communications & Power Industries Completes Acquisition of Malibu Research Associates 2Health News:Communications & Power Industries Completes Acquisition of Malibu Research Associates 3
2008 Presidential Hopefuls Fail to Respond to Questions About Obesity in U.S.URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation ProgramsOakwood is First Healthcare System in Southeast Michigan to Post Pricing Information on Web SiteHooters of Gulfport Makes the Largest Contribution towards the $250,000 Donation to the V Foundation for Cancer ResearchCommunications & Power Industries Completes Acquisition of Malibu Research AssociatesAUDIO from Medialink and Safe Kids Worldwide: Teaming Up to Keep Kids Safe Around Cars
Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Webcast of QIAGEN N V s 28Nasdaq 3A QGEN 29 Second Quarter 2009 Financial Results Call Set for August 11 13355 1Webcast of QIAGEN N V s 28Nasdaq 3A QGEN 29 Second Quarter 2009 Financial Results Call Set for August 11 13355 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 1VIASPACE Pursuing Renewable Energy Business in Asia 13353 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 1Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 2Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 4Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 5Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 6
[0] Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders[0] Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer[0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes
Other Medicine Technology:ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting 2ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting 3Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 2Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 3Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 4Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |